Charlie’s Holdings, Inc. (OTCMKTS:CHUC – Get Free Report) was the target of a large decline in short interest in the month of October. As of October 15th, there was short interest totaling 13,006 shares, a decline of 49.2% from the September 30th total of 25,596 shares. Based on an average daily trading volume, of 115,568 shares, the short-interest ratio is currently 0.1 days. Currently, 0.0% of the shares of the company are sold short.
Charlie’s Stock Performance
Shares of OTCMKTS:CHUC traded down $0.01 during trading on Monday, reaching $0.13. 74,463 shares of the company’s stock traded hands, compared to its average volume of 84,889. The stock has a market capitalization of $36.61 million, a P/E ratio of -13.04 and a beta of 1.39. Charlie’s has a 12 month low of $0.01 and a 12 month high of $0.37. The company has a 50 day moving average of $0.16 and a 200-day moving average of $0.23. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.65 and a quick ratio of 0.40.
Charlie’s (OTCMKTS:CHUC – Get Free Report) last issued its earnings results on Monday, August 17th. The company reported ($0.01) earnings per share (EPS) for the quarter. The business had revenue of $3.80 million during the quarter. Charlie’s had a negative return on equity of 63.51% and a negative net margin of 7.47%.
Charlie’s Company Profile
Charlie’s Holdings, Inc is a consumer products company focused on the vaping and nicotine-products industry. The company has been associated with the development, manufacturing, marketing and distribution of electronic cigarettes, vapor products and e-liquids.
Its product portfolio has included flavored nicotine e-liquids and vapor devices sold under brands such as Charlie’s Chalk Dust and Pachamama. These products have been marketed through specialty retailers, distributors and other channels serving adult nicotine consumers.
Publicly available information about the company’s current operations, geographic reach and leadership is limited.
See Also
- Five stocks we like better than Charlie’s
- AbbVie’s Humira Era Is Fading, But Its New Growth Engines Face Another Test
- GLP-1 Focus or Broader Peptide Exposure: Which ETF Has the Edge?
- Mortgage Rates Froze U.S. Housing, But These 3 Overseas Markets Still Pay Double Digits
- Big Tech Is Spending Billions on AI—These 5 Stocks Are Getting Paid
Receive News & Ratings for Charlie's Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charlie's and related companies with MarketBeat.com's FREE daily email newsletter.
